Australia Regulates Supplements Like Drugs, but Nobody Checks Whether They Work
Australia puts supplements and pharmaceuticals under the same agency, which looks strict; but efficacy is neither reviewed before market nor tested during production — the impression of "good" was installed by marketing and cross-border policy.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Australians taking pills is a tradition, not a climate
The soil this industry grew in wasn't the natural environment but four social habits: a sparse population that self-medicates, pharmacists who also diagnose and dispense, naturopathic industry bodies dating to the 1920s, and health food shops akin to food-as-medicine. Stack those four together and Australians take it for granted that you solve health problems without going to hospital. Black Moth (澳佳宝) started as a naturopathic clinic, and only after the second generation took over did it translate that into products the mainstream system could recognise — turning "a spoonful of fish oil a day" into a standardised fish oil capsule.
The contract manufacturers are the industry's foundation
Pen Pharmaceuticals, which appeared in 1974, was Australia's first company focused on contract manufacturing of supplements, and by around 2003 it was producing roughly 70% of Australia's vitamins, minerals and herbal products. Its value lay in process know-how: tablets, compound ingredients, sealing the gelatin shell and oils of soft capsules, blend uniformity in powders, stability in liquids — each is its own set of solutions. In the 1980s and 90s a new generation of contract manufacturers extended service in both directions, moving from pure production (CMO) to CDMO covering formulation, ingredients, trial production, labelling, packaging, testing, and registration for export. The brand only has to hand over a concept and the factory can turn it into a product ready to sell.
Registration means nobody looks before it goes on sale
Australia legislated in 1989, putting the TGA in charge of both pharmaceuticals and supplements, and every product needs an AUST number. Most supplements fall into the AUSTL category: only low-risk ingredients permitted by the TGA, only low-level health claims, and a company gets a number just by applying — the TGA does no pre-market review, only post-market spot checks. By around 2010 Australia had roughly ten thousand complementary medicines, and nearly 98% of them sat in this registration system. Only prescription medicines, over-the-counter medicines and a small number of high-risk supplements enter the AUSTR tier, where the TGA must assess safety, quality and efficacy in advance.
It looks strict, but the efficacy bar is very loose
Put contract manufacturing and regulation together and you see that GMP only guarantees the factory produces consistently to the standard the brand gives it, and that problems can be traced to a batch for recall — it is not itself responsible for whether the product works. The TGA side only handles declarations and issuing numbers; efficacy is explained by the brand itself. So "Australia regulates supplements like drugs" is not wrong, but it is misleading: the method of control is the same, while the degree of control over the efficacy part differs enormously. The whole system does no effective upfront oversight of whether a product actually works, and there is a risk of disconnect between the brand and the product's efficacy.
The marketing was copied from Centrum, not invented
Radek Sali, who became CEO in 2008, did not conjure a marketing plan out of thin air. He researched the industry and found the best seller among peers was Centrum, and feedback from retailers was: Centrum doesn't give the channel much margin, but you can't fight it when it runs ads on TV all year, has great athlete endorsements, and consumers walk into the pharmacy asking for it by name. Sali wanted to replicate that at Swisse. He started with Australia's national sport, cricket — the men's team captain, buying very short ad slots only during the hottest summer cricket broadcasts, so a limited budget could still appear at key moments. But the female-dominated sales channel wasn't moved; one buyer didn't watch cricket and didn't know the athlete. He asked his mother what she liked to watch, and she said a dance variety show, and the strategy pivoted to spoken endorsements inside entertainment content.
Selling health as a lifestyle, not a pill
Swisse's bigger promotional push rode on Oprah and Ellen, and signed a three-year deal with the actress Nicole Kidman, extending its reach from Australia to the United States. By 2012 Swisse had 25 brand ambassadors, had shot more than 80 TV commercials in the previous 12 months, and reached annual revenue of A$183 million, with marketing spend of A$40-50 million a year — reportedly at one point the highest marketing spend of any consumer brand in Australia. Its ads didn't stress efficacy or ingredients; they mainly presented a state of being energetic, self-disciplined and good-looking — converting health into a lifestyle consumers aspire to. In 2012 Swisse took more than 20% market share in Australian supermarkets and more than 10% in pharmacies.
The growth engine was found in Chinese pharmacies
Swisse spent heavily on the US market without much success, and on returning to Australia found that Swisse sold extremely well in pharmacies in Chinese-concentrated areas, with some stores selling at ten times the level of an ordinary store — because students and Chinese migrants bought it in bulk to carry back to China or resell online, that is, daigou. Two policy turns came in 2015: in March the Hangzhou cross-border e-commerce comprehensive pilot zone was approved, and in June China and Australia signed a free trade agreement that took effect that December. The FTA mainly affected ordinary trade; Australian official statistics put the tariff on vitamins and supplements generally at 3% to 10%, while Black Moth itself estimated an average of 20%, and after the agreement it was said the rate could fall to zero within four years. Cross-border e-commerce goes through bonded warehouses, platforms buy in bulk, logistics time and cost drop sharply, and such goods are treated in policy as for personal use, so they don't have to go through the registration and filing process for supplement imports.
The brand was bought; the impression stayed put
In September 2015 the Hong Kong-listed company Biostime completed the acquisition of a controlling stake in Swisse, and two years later completed a full buyout, a deal of about A$1.7 billion, or RMB 8.7 billion. For Swisse the deal carried little premium; for Biostime it added a large chunk of business revenue and imagination. All those Swisse ads on Hunan TV variety shows now are, in theory, a Chinese supplement company spending the money, yet the brand can still say it is an Australian supplement brand, and consumers can still drape their old vague good impression of Australia over it — a large share of the acquisition's core value is deposited in brand goodwill.
In their own words · checked verbatim
The GMP system itself is not responsible for the product's efficacy; it can only prove that the contract manufacturer produced to the standard the brand gave it.
GMP这个体系本身不对产品的有效性负责 它只能证明代工厂是按照品牌给到的标准去生产的
The whole system actually looks strict but is loose in practice, especially when it comes to the efficacy part.
整个体系其实是 看上去严格 实际上宽松的 就尤其是对于功效这个部分
This looseness means that no part of the system does any effective upfront oversight of the product's actual effect.
这种宽松就导致了 不管是体系的哪个部分 对于产品的实际效果 都没有进行任何的 有效的前期监督
It doesn't stress efficacy or ingredients; it mainly presents a state of being energetic, self-disciplined and good-looking — turning health into a lifestyle consumers aspire to.
它不太强调功效和成分 它主要呈现一种精力充沛 积极自律 外表良好的状态 就是把健康转化成了一种 令消费者向往的生活方式
The supplement industry has no particular barrier to entry; if everyone doesn't compete on marketing, for now there's nothing else to compete on.
保健品行业并没有什么特别的门槛 大家如果不拼营销的话 暂时也没有找到下一步可以拼的东西
When consumers face something they're unfamiliar with, it's actually very easy for them to string together other familiar and trustworthy concepts to understand the unfamiliar thing.
消费者面对自己不熟悉的东西的时候呢 其实很容易把一些别的熟悉 又可信的概念串联在一起 去理解这个不熟悉的东西
We easily remember very simple concepts or judgments, so simple that you forget how many layers of logic lie behind them, so the more a business idea looks like common sense, the more it's worth asking one more question: how did it come about, and how did it become so-called common sense?
我们容易记住一些特别简单的概念或者判断 简单到让你忘掉它背后 原来有那么多层的逻辑 所以越像常识的商业观念呢 越值得多问一句 它到底是怎么来的 又是怎么变成所谓的常识的
Figures
| Pen Pharmaceuticals' share of Australian vitamin, mineral and herbal product production | about 70% (around 2003) | 12:05 |
| Swisse annual revenue | A$183 million (2012) | 26:09 |
| Swisse annual marketing spend | A$40-50 million | 26:09 |
| Swisse brand ambassadors and TV commercials in 12 months | 25 brand ambassadors, more than 80 TV commercials (2012) | 26:09 |
| Swisse market share in Australian supermarkets | more than 20% (2012) | 28:11 |
| Swisse market share in Australian pharmacies | more than 10% (2012) | 28:11 |
| Size of Biostime's acquisition of Swisse | about A$1.7 billion, or RMB 8.7 billion | 35:16 |
| Tariff on Australian vitamins and supplements | official statistics generally 3% to 10%; Black Moth itself estimated an average of 20% | 33:15 |
| By-Health selling expense ratio | 42% (2026 half-year report) | 31:14 |
Glossary
- TGA / Therapeutic Goods Administration
- Australia's dedicated agency regulating both pharmaceuticals and supplements, the counterpart to the US FDA.
- AUSTL / registration listing number
- The category most supplements use, obtained simply by the company applying; the TGA does no pre-market review, only post-market spot checks.
- AUSTR / assessed registration number
- For prescription medicines, over-the-counter medicines and a small number of high-risk supplements, requiring the TGA to assess safety, quality and efficacy in advance.
- GMP / Good Manufacturing Practice
- A common international standard at the production level, ensuring consistent production to standard and traceable recalls, but not responsible for efficacy.
- CMO / CDMO / contract manufacturing / contract development and manufacturing
- A CMO takes only the production step; a CDMO also takes on development work such as formulation, ingredients, trial production and regulatory filings.
How to listen
Investors and founders looking at consumer brands, supplements and cross-border e-commerce, plus anyone doing brand marketing or interested in where regulatory arbitrage exists.
14:35-15:05 has a stretch of transcription garbage that can be skipped without affecting comprehension.